Navigation Links
Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
Date:4/2/2009

  • The immunogenicity was comparable to that of the U.S. licensed product, JE-VAX(R).
  • Intercell's vaccine demonstrated an overall clinical safety profile similar to placebo.
  • Further, Intercell's Japanese Encephalitis vaccine had a more favorable local tolerability profile in the head-to-head study with JE-VAX(R).

About Intercell AG

Intercell AG is an innovative biotechnology company that designs and develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the company's first product on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin and the Statens Serum Institut.

The Company's development pipeline includes Phase II vaccine programs for Pseudomonas (in-house development) and S. aureus, which is being developed with Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter Phase III testing in 2009. Intercell is also in clinical trials of a vaccine enhancement patch with injected Pandemic Influenza vaccines (one shot plus patch). In addition, four other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG a
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
2. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
3. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
4. Iomai Stockholders Approve Merger With Intercell Subsidiary
5. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
6. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
7. China Biologic Products Announces Strong 2008 Results
8. Senetek PLC Announces New Investor Communication Hotline
9. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
10. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
11. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
(Date:7/24/2014)... Although most natural and synthetic processes prefer to ... potential or energyit is within the realm of ... experience constant changes in energy and phases, such ... These conditions allow humans to regulate their body ... rumble with seismic activity. , But even ...
(Date:7/24/2014)... -- Research and Markets has announced the ... Instruments Market 2014-2018" report to their offering. ... is the study of the gene and its functions ... functions of proteomes or sets of proteins by using ... the mapping of genes and DNA sequencing to understand ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... NORWOOD, Mass., Nov. 19 Advanced Instruments, ... has acquired 100% of the,shares of Mart ... of the,transaction were not disclosed. Mart ... of,instruments. These systems create custom environments for ...
... on Smart Coatings Cites Immediate Opportunities in ... Paint, and Smart Glass -, LITTLE FALLS, N.J., ... that they will no longer reimburse expenses related,to most ... and coatings industries to sell antimicrobial coatings,according to analysts ...
... Siemens Medical Solutions, (http://www.usa.siemens.com/healthcareit ) continues ... clinical and financial workflows through,Soarian(R), its next-generation, ... Assembly and Annual Meeting of the,Radiological Society ... to 30 at,McCormick Place in Chicago (Booth ...
Cached Biology Technology:Advanced Instruments Acquires Mart Microbiology B.V. 2Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S. 2Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian 2Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian 3
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... CINCINNATIBacterial contamination in water-damaged buildings has been identified ... infection and respiratory conditions like asthma. Which specific ... unknownmaking it difficult for public health officials to ... of the problem. In a new ...
... Review, 2012 -- a new congressionally mandated report from ... Comprehensive Everglades Restoration Plan (CERP), a multibillion-dollar, joint federal ... decline while meeting growing demands for clean water and ... CERP, which was launched in 2000 by the U.S. ...
... study published in the June 2012 issue of the ... found that young children who have been investigated for ... mental health problems and that very few receive treatment for ... Child and Adolescent Well-Being II (NSCAW II), a group of ...
Cached Biology News:Research identifies specific bacteria linked to indoor water-damage and mold 2Child welfare investigation predicts mental health problems in young children 2
ERalpha (Ser 104/106)...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Biology Products: